Christopher R Smith

7PUBLICATIONS
50CO-AUTHORS
Molecular targetsRadiation and matterBiomolecular modelling and designGene and molecular therapyMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.

Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos

|Dec 29, 2023
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.

Christopher R Smith, Dan Chen, James G Christensen

|Aug 08, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.

Lars D Engstrom, Ruth Aranda, Laura Waters

|Apr 28, 2023
Selected Approaches to Disrupting Protein-Protein Interactions within the MAPK/RAS Pathway.

Stephen J Harwood, Christopher R Smith, J David Lawson

|Dec 22, 2022
Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits.

Christopher R Smith, Svitlana Kulyk, Misbha Ud Din Ahmad

|Oct 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.

Jill Hallin, Vickie Bowcut, Andrew Calinisan

Pageof 2

Frequent Collaborators

5 joint publications

J David Lawson

4 joint publications

Matthew A Marx

3 joint publications

Jill Hallin

3 joint publications

Lars D Engstrom